Oncology Central

Long-term efficacy of 90Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms

0

Aim: To determine the efficacy of 90Y [DOTA0, D-Phe1, Tyr3]-octreotate (DOTATATE) in 67 patients with pancreatic and small bowel neuroendocrine tumors (NETs). Patients & methods: The primary efficacy end point was overall survival (OS) and secondary end points were progression-free survival (PFS) and tumor response.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.